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Abstract Prostate cancer is one of the most common
malignancies in men and is predicted to be the second
leading cause of cancer-related deaths. After 6–18 months,
hormone ablation treatment results in androgen-indepen-
dent growth of cancer cells, metastasis and progression. The
mechanism of androgen-independent growth of prostatic
carcinoma cells is still unknown. Identification of factors
that facilitate the transition from androgen-dependent to
independent states is crucial in designing future diagnostics
and medication strategies. To understand the biochemical
meaning of hormone dependency deprivation, glycoproteins
enriched profiles were compared between DU145 (hormone
non-responding) and LNCaP (hormone responding) prostate
cancer cells. These results allow for anticipation on the
important role of glycosylation in malignant transformation.
Both Tn antigen and complex antennary N-oligosaccharides
were recognized. Their occurrence might be involved in the
development and progression of tumor, and failure of hor-
mone ablation therapy. Among identified proteins in
androgen-sensitive cells nucleolin (P19338) was found that
is widely described as apoptosis inhibitor, and also trans-
porter of molecules from the membrane to the cytoplasm or
nucleus. In addition, 14-3-3 protein family (P27348,
P31946, P61981, P63104, P62258, Q04917, and P31947)
was investigated across available databases as it forms sta-
ble complexes with glycoproteins. Our studies indicate that
isoforms: sigma and eta were found in androgen-dependent
prostate cancer cells, while other isoforms were present in
androgen non-responding cells. 14-3-3 binding partners are
involved in cancer pathogenesis. These findings may con-
tribute to a better understanding of prostate cancer tumori-
genesis and to a more efficient prognosis and individual
therapy in a future. However, it still remains to be revealed
how important those changes are for androgen dependency
loss in prostate cancer patients carried out on clinically
relevant populations.
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Introduction
Patients with advanced prostate cancer (PCa) initially
benefit from androgen ablation therapy, which leads to the
temporary tumor remission due to apoptosis of the andro-
gen-sensitive tumor cells [1]. However, recurrence of
androgen-independent tumor is inevitable for most patients
and renders the conventional hormone therapy ineffective
[Fig. 1]. Despite the extensive knowledge we currently
have, the PCa mechanisms of the loss of androgen
dependency by cancer cells that ultimately leads to the
formation of metastases, is not recognized yet. Under-
standing the mechanism and identification of factors that
facilitate the transition from androgen-dependent to inde-
pendent state is crucial in designing future diagnostics and
medication strategies. In the present study, we revealed
lectin-enriched proteome changes in the androgen depen-
dency loss between androgen-responding and androgen-
nonresponding prostate cancer cell lines. The rationale to
focus on glycoproteome is based on the fact that 30 of 38
proteins on the list of biomarkers, proteins involved in
disease formation, currently used in clinical diagnostic are
known to be glycosylated [2]. Aberrant protein glycosyla-
tion may be a result of various factors, including inflam-
mation or cancer development. These changes result in
abnormal alterations of biological functions, protein fold-
ing, adhesion, metastasis, and molecular recognition. The
site(s) of protein glycosylation and the structure of the
oligosaccharides are altered during initiation or progression
of the disease; however, we have focused on analysis of
glycosylated subproteome for the reason that affinity
reagents reduce sample complexity, and also enrich reli-
ability of the results in biologically and clinically important
information.
Glycoproteomic studies are complicated by the micro-
and macro-heterogeneity of glycoproteins in comparison to
their non-glycosylated forms. Macro-heterogeneity is
related to variability in the number of potential sites gly-
cosylated in the same protein, whereas micro-heterogeneity
is represented by the possibility to carry a variety of glycan
structures at the same glycosylation site. Nature gives the
full advantage of enormous diversity of glycans expressed
in all living organisms by creation of lectins able to rec-
ognize discrete glycans that mediate specific physiological
or pathological processes.
There are many known glycoprotein enrichment strate-
gies, including hydrazine chemistry, titanium dioxide,
enzymatic method, and lectin technique. However, only
lectin affinity chromatography (LAC) allows detecting
target glycans on specific protein carriers, and is routinely
utilized methodology designed to concentrate glycopro-
teins [3]. Therefore, to facilitate isolation of glycoproteins
from the total cell extract, the LAC technique was applied.
The highly abundant proteins often do not possess affinity
for lectins. For that reason, lectins may act as enriching
factors for cancer-related aberrant species that may further
be validated as potential cancer biomarkers. To measure
the changes in protein patterns with the specific glycan
structure in prostate cancer cells, we proposed a lectin
affinity-based mass spectrometry method.
Low specificity and efficiency of lectins has been dis-
cussed in numerous studies [4–6]. Those limitations are the
Fig. 1 Performance of
hormone therapy
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result of insufficient binding affinity, leading to poor sen-
sitivity in analytical assays, and the lack of availability
glycan-binding reagents for less studied structures. How-
ever, impressive achievements in MS technologies and
instrumentation, also miniaturization benefits in increased
sensitivity of proteomic investigations, and resulted in
minimizing these drawbacks.
Abnormal glycosylation, such as, e.g., increased glycan
size and extra branching of glycan chains with oversialy-
lation and fucosylation, is closely associated with cancer
progression. The presence of characteristic glycans
including Tn antigens, and tri- and tetra-antennary N-gly-
cans on the protein surface in healthy and malignant cells
may be valuable for understanding pathological mecha-
nisms of cancer progression, resistance to treatment, and
for identifying specific cancer biomarkers [7]. Therefore,
for the purpose of these studies we have selected both VVL
(Vicia Villosa) and Phaseolus vulgaris agglutinin (PHA-L)
lectins. VVL recognizes preferentially terminal N-acety-
lgalactosamine residue characteristic for the Tn antigen,
whereas PHA-L binds to antennary N-oligosaccharides.
The presence of glycosylation sites was determined by a
simple method that utilizes the Swiss-Prot database and the
Mascot search engine [8].
It was confirmed by the three biological, and two tech-
nical replicates, that the presented approach provides
reproducible results with precision sufficient to distinguish
differences in protein profiles between analyzed samples.
Selected cell lines are characterized by different properties
in terms of androgen dependency. DU145 cell line was
derived from brain metastasis, and is an example of the cells
found in patients who do not respond to hormonal treatment,
mostly in the terminal state [9]. LNCaP cell line served as a
model of tumor in patients who respond to androgen abla-
tion therapy [10]. The cell lines model provides an addi-
tional advantage, as the amount of sample required for MS
analysis is not limited, what makes cell lysates suitable for
extensive fractionation. Furthermore, cell cultures allow for
enrichment of proteins that are present at higher concen-
trations than in the patients’ serum or plasma.
Materials and methods
DU145 (androgen-insensitive) and LNCaP (androgen-sen-
sitive) human prostate cancer cell lines were obtained from
the American Type Culture Collection (USA). Cells were
cultured in the RPMI-1640 medium (Sigma-Aldrich,
Poland) supplemented with 10 % heat-inactivated fetal
bovine serum (Gibco, Poland), 1 % L-glutamine, 100 U/ml
penicillin, 100 lg/ml streptomycin at 37 C in a humidified
atmosphere of 5 % CO2 [9, 10]. For the analysis, LNCaP
and DU145 cell cultures were rinsed with PBS and
homogenized three times on ice by sonication (5 s each) in
700 ll sample buffer consisting of 50 mM Tris/HCl pH 7.5
supplemented with 1 mM EDTA and 7 ll of proteinases
inhibitor cocktail (Sigma-Aldrich, Poland). The homoge-
nate was left on ice with 1 % Triton X-100 and 7 ll 3 %
protamine sulfate (1 h), and then centrifuged at 16,000 9 g
for 1 h at 4 C (Ultracentrifuge L7-65 Beckman, USA).
Protein concentration was determined in supernatants with
the aid of a Bradford assay kit (Sigma-Aldrich, Poland). An
efficient technique for glycoprotein identification in prostate
cancer cells characterized with different androgen depen-
dency states was developed. Combination of modern
methods involved: glycoproteins isolation using LAC, gly-
coproteins’ separation based on the one-dimensional
sodium dodecyl sulfate polyacrylamide gel electrophoresis
(SDS-PAGE), specific lectin–protein interactions verifica-
tion using Western-blotting, separation of peptides and
identification utilizing capillary chromatography combined
with tandem mass spectrometry (nanoLC-MS/MS) (Fig. 2).
Isolation of glycoproteins
Homogenates containing 1.2 mg of protein were incubated
with either VVL or PHA-L lectins linked to agarose
(Vector Lab, Poland) for 1 h at room temperature in the
presence of 70 ll 10 mM HEPES buffer pH 7.5 with
0.15 M NaCl (Sigma-Aldrich, Poland), followed by 16 h
incubation at 4 C. Subsequently, suspensions were cen-
trifuged at 22,000 9 g for 5 min. at 4 C. Precipitates were
washed three times with PBS (Sigma-Aldrich, Poland),
followed by incubation at 100 C for 10 min in 50 ll of a
buffer 50 mM Tris/HCl pH 6.8, 5 % BME, 2 % SDS, 10 %
glycerol (Bio-Rad, Poland), 1 mM EDTA (Sigma-Aldrich,
Poland), and centrifuged at 22,000 9 g for 5 min at room
temperature. Seventy microliters of supernatant were col-
lected to the siliconized Costar tubes.
SDS-PAGE
One-dimensional electrophoresis was performed. Thirty
microliters of glycoprotein containing supernatant per lane
was separated by 10 % SDS-PAGE, according to Laemmli
protocol [11]. One part of the gel was stained with Coo-
massie Brilliant Blue G (CBB G) (Sigma-Aldrich, Poland)
prior nanoLC-MS/MS analysis, and the second was electro
transferred onto the PVDF membrane (Roche, Poland) to
confirm the type of protein-lectin interactions.
Western blot analysis
The presence of specific glycan epitopes, Tn antigens and
highly complex antennary N-oligosaccharides was con-
firmed by VVL and PHA-L lectins, respectively. The
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blotted membranes were treated with casein solution as a
blocking agent for 1 h at room temperature, washed three
times with tris buffered saline (TBS) buffer (Sigma-
Aldrich, Poland), and subsequently incubated with VVL or
PHA-L lectin for 2 h, according to manufacturer’s rec-
ommendations. After extensive washes, the blots were
incubated with alkaline phosphatase substrate kit II (Vector
Lab, Poland). Simultaneously, negative controls were
included in the presence of lectins blocked with 0.2 M
GalNAc (Sigma-Aldrich, Poland), and, respectively, 0.1 M
CH3COOH (Sigma-Aldrich, Poland), that are responsible
for blocking glycan-binding sites on the receptor surface.
The nonspecific interactions were not considered for fur-
ther investigations (Fig. 3).
Extraction of peptides
The spots were excised from the CBB-stained gel with a
scalpel, chopped into cubes, rinsed with water, and trans-
ferred into siliconized tubes. CBB stain was removed with
100 mM NH4HCO3 and an equal volume of acetonitrile was
added after 10–15 min. Then, gel pieces were treated with
100 % acetonitrile and re-swollen in 12 ng/lL trypsin
(Promega, USA) in 50 mM NH4HCO3 on ice for 45 min.
The supernatants, which were not absorbed by gel particles,
were removed, and gel pieces were immersed in 50 mM
NH4HCO3 and incubated overnight at 37 C. After com-
pletion of digestion, the supernatants were transferred into
another tube, followed by addition of 50 mM NH4HCO3,
and after 10–15 min, an equal volume of acetonitrile was
added. The samples were incubated under shaking at 37 C
for 30 min. Extraction of peptides was repeated twice with
5 % formic acid (v/v) in acetonitrile, and combined extracts
were evaporated to dryness in a vacuum centrifuge.
Capillary chromatography combined with tandem mass
spectrometry
Dried samples were prepared for nanoLC-MS/MS by dis-
solving them in 11 ll 0.1 % trifluoroacetic acid (TFA)
(Sigma-Aldrich, Poland). The nanoLC-MS/MS analysis,
used to separate the digests, was performed with the
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Fig. 2 Proteomic strategy for
identification of glycoproteins
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ultimate LC micro chromatography system (LC Packings/
Dionex, USA). The separation was made on a capillary
column filled with the PepMap reversed-phase material
(15 cm long, 75 lm ID, C18, 2–3 lm particle size, and
100 Å pore size, LC Packings/Dionex, USA). The gradient
was formed using 0.1 % HCOOH in 98:2 (v/v) water/
acetonitrile solution (solvent A) and 0.1 % HCOOH in
20:80 (v/v) water/acetonitrile solution (solvent B), and it
was delivered at a flow rate of 400 lL/min. The system
was controlled by the Chromeleon software (Dionex,
USA). A gradient was produced from 2 to 50 % B in
30 min and up to 90 % B at 35 min, then kept until 45 min,
and again reduced to 2 % until 55 min. The chromato-
graphic system was coupled directly to the Esquire 3,000
quadrupole ion-trap mass spectrometer (Bruker Daltonics,
Germany) using the home-made ‘‘black-dust’’ nanoelec-
trospray emitter [12]. The instrument operated in a posi-
tive-ion mode. During analysis, two most intense peaks
(threshold above 100,000) in the range 450–1,800 m/z were
automatically fragmented in data-dependent acquisition
mode. The acquired spectra were analyzed using the Bru-
ker Data Analysis 4.0 software and were identified using
Mascot 2.3.01 algorithm against the Swiss-Prot/TrEMBL
sequence database 57.15 (515203 sequences; 181334896
residues). Search parameters were set as follows: taxon-
omy: human, modification: carbamidomethyl (fixed), up to
1 missed cleavage, peptide charges ?1, ?2, and ?3, mass
tolerance 0.8 Da for precursor mass, and 0.6 Da for frag-
ment mass. The probability score evaluated by the software
was used as criterion for correct identification, and also for
comparison of molecular weight based on SDS-PAGE.
Proteins with more than two-fragmented peptides detected
were considered, and an additional criterion was a Mowse
score above 40. Forty-nine of the androgen-independent
cancer cell candidates were identified using capillary liquid
chromatography combined with mass spectrometry based
on these criteria (Table 1).
Database searching
In addition, all the identified proteins were searched against
UniProtKB, Osprey and Panther Database to establish their
molecular functions and interactions (Fig. 4). Numerous
interaction nodes with oncogenes and proteins described as
contributing directly to cancer progression were found.
Results and discussion
Based on the available database information proteins con-
tributing to cancer progression have been confirmed, there-
fore they can be the key to understand the mechanism of
Fig. 3 Example of lectin–
protein interactions blots
(LNCaP proteins precipitated
and detected with VVL lectin)
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Table 1 Biomarker candidates of androgen dependency loss
Protein name Protein
ID
Number of identified
peptides (based on
MS/MS spectra)
Average
score
Standard
deviation
Present
antigen
TLN1_HUMAN talin-1 Q9Y490 9 437 53 Antennary
N-glycan
ITA9_HUMAN integrin a-9 precursor Q13797 7 359 64 Tn
1433T_HUMAN 14-3-3 protein h P27348 8 397 51 Tn
1433B_HUMAN 14-3-3 protein b/a P31946 5 285 46 Tn
1433G_HUMAN 14-3-3 protein c P61981 8 275 62 Tn
1433Z_HUMAN 14-3-3 protein f/d P63104 6 212 54 Tn
TBB4_HUMAN tubulin b-4 chain Q13509 10 417 61 Tn
TBB1_HUMAN tubulin b-1 chain Q9H4B7 7 391 59 Antennary
N-glycan
MYH10_HUMAN myosin-10 P35580 11 326 73 Tn/antennary
N-glycan
ACTZ_HUMAN a-centractin (centractin) P61163 6 237 62 Tn
ACTC_HUMAN actin, a cardiac muscle P68032 5 178 73 Tn
EF1A2_HUMAN elongation factor 1-a 2 Q05639 4 183 56 Tn
EF1B_HUMAN elongation factor 1-b P24534 7 283 49 Antennary
N-glycan
EF1G_HUMAN elongation factor 1-c P26641 6 219 65 Tn
COFA1_HUMAN collagen a-1(XV) chain precursor P39059 6 290 54 Tn
CO5A2_HUMAN collagen a-2(V) chain P05997 4 146 69 Tn
AT1A2_HUMAN sodium/potassium-transporting ATPase a-2 P50993 4 119 76 Tn
ATPO_HUMAN ATP synthase subunit O P48047 5 89 36 Tn
VDAC3_HUMAN voltage-dependent
anion-selective channel protein 3
Q9Y277 4 164 55 Tn
G6PI_HUMAN glucose-6-phosphate isomerase P06744 5 183 63 Tn
PGM2_HUMAN phosphoglucomutase-2 Q96G03 6 192 68 Tn
KCRB_HUMAN creatine kinase B-type P12277 6 117 53 Tn/antennary
N-glycan
VDP_HUMAN general vesicular transport factor p115 O60763 5 192 49 Tn
EEA1_HUMAN early endosome antigen 1 Q15075 5 162 62 Antennary
N-glycan
ROA1_HUMAN heterogeneous nuclear ribonucleoprotein A1 P09651 7 183 69 Antennary
N-glycan
RU2A_HUMAN U2 small nuclear ribonucleoprotein A’ P09661 5 127 49 Tn
HNRH1_HUMAN heterogeneous nuclear ribonucleoprotein H P31943 6 182 37 Tn
HNRPF_HUMAN heterogeneous nuclear ribonucleoprotein F P52597 7 172 53 Tn
RL7_HUMAN 60S ribosomal protein L7 P18124 5 128 59 Tn
NUCL_HUMAN nucleolin P19338 8 371 33 Tn
RL13_HUMAN 60S ribosomal protein L13 P26373 6 219 58 Tn
IF39_HUMAN eukaryotic translation initiation factor 3 subunit 9 P55884 4 163 38 Tn
RT07_HUMAN 28S ribosomal protein S7 Q9Y2R9 4 149 49 Tn
YBOX1_HUMAN nuclease-sensitive element-binding protein 1 P67809 6 238 40 Tn
UGDH_HUMAN UDP-glucose 6-dehydrogenase O60701 4 217 58 Tn
ACADV_HUMAN very long-chain specific
acyl-CoA dehydrogenase
P49748 5 173 53 Antennary
N-glycan
ASPH_HUMAN aspartyl/asparaginyl beta-hydroxylase Q12797 4 115 46 Tn
NQO1_HUMAN NAD(P)H dehydrogenase (quinone) 1 P15559 3 93 38 Antennary
N-glycan
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hormone dependency loss and might lead to the development
of new treatment methods. Our special concern was dedi-
cated to glycosylated nucleolin (P19338) and 14-3-3 protein
family bounded with glycoproteins (P27348, P31946,
P61981, P63104, P62258, Q04917, P31947), as these mol-
ecules are frequently reported to be involved in a variety of
cellular processes, including tumorigenesis (Fig. 4).
Nucleolin carrying Tn antigen was found to be expres-
sed in DU145 cells, and at the same time, deficient in
LNCaP cells. In spite of its major nuclear localization,
nucleolin is also known to shuttle between the nucleus and
the cytoplasm, and during this trafficking it controls the
organization of nuclear chromatin, RNA, DNA and ribo-
somes [13]. It is commonly known, that surface nucleolin
is glycosylated and that N-glycosylation is crucial for its
expression on the cell surface [14]. The presence of nu-
cleolin on the cell surface seems to be an important factor
in androgen dependency, since the hormone-sensitive cells
do not contain this protein. This may suggest that the
hormone-refractory cells evolved mechanism of blocking
the extension of O-GalNAc, resulting in formation of
incomplete glycans. Nucleolin is abundant in proliferating
cancerous cells, and high levels of nucleolin expression are
related to poor clinical prognosis [14–19]. In fact, with the
increase of malignancy in patients, the raise of nucleolin
levels present in cytoplasmic and membrane fractions is
observed [17, 18]. In addition, P-selectin binds tumor cell
surface nucleolin, but not nucleolin expressed in the
cytoplasm or nucleolus, what may suggest a mechanism
linking nucleolin to P-selectin-induced signal transduction
pathways that regulate cell adhesion through activation of
the a5b1 integrin. Because tyrosine kinase activity is
important for the P-selectin-mediated nucleolin/PI3K
interaction, tyrosine-phosphorylated nucleolin might par-
ticipate in PI3K activation [19]. Furthermore, introduction
of the anti-cancer aptamers that specifically bind to nu-
cleolin resulted in inhibition of nucleolin function and
cancer cell growth in vitro and in vivo [20]. We have
previously performed studies on human melanoma cell
lines and have shown that nucleolin may act as a marker of
tumor progression, as its synthesis is correlated with
increased cell proliferation [14]. Indirect immunofluores-
cence staining and laser scanning confocal microscopy
were used to detect the presence of nucleolin in nucleolus,
cytoplasm, and on the cell surface of human prostate cells.
In contrast to nuclear nucleolin, the surface-expressed and
cytoplasmic nucleolins exhibited Tn antigen, which was
identified by simultaneous immunofluorescence staining
and VVL-positive glycoproteins in confocal microscopy
[14]. In conclusion, many questions remain to be resolved
concerning the expression of nucleolin at the surface of
cells and its trafficking, also in relation to the involvement
of glycosylation in these processes. Further studies on the
expression levels and translocation of nucleolin to the cell
surface will certainly provide new insights into the mech-
anisms of androgen dependency loss, cancer development
and progression.
The 14-3-3 proteins family involved in a growing
number of cell biology processes, including modulation of
cellular signaling pathways, cell death, cell cycle, and
Table 1 continued
Protein name Protein
ID
Number of identified
peptides (based on
MS/MS spectra)
Average
score
Standard
deviation
Present
antigen
PKHA5_HUMAN pleckstrin homology
domain-containing family A member 5
Q9HAU0 4 72 39 Tn
NPC1_HUMAN niemann-pick C1 protein O15118 5 81 53 Antennary
N-glycan
IQGA1_HUMAN ras GTPase-activating-like protein IQGAP1 P46940 3 148 58 Tn/antennary
N-glycan
RAB8A_HUMAN ras-related protein Rab-8A P61006 4 219 64 Tn
RAB8B_HUMAN ras-related protein Rab-8B Q92930 6 246 38 Tn
RAN_HUMAN GTP-binding nuclear protein Ran P62826 4 173 46 Tn
PSMD5_HUMAN 26S proteasome non-ATPase regulatory subunit 5 Q16401 3 116 58 Tn
IMB3_HUMAN importin b-3 O00410 6 82 47 Tn
PHB_HUMAN prohibitin P35232 7 412 46 Tn
COMT_HUMAN catechol O-methyltransferase P21964 4 184 39 Tn
TGM2_HUMAN protein-glutamine c-glutamyltransferase 2 P21980 3 94 64 Antennary
N-glycan
Average score was calculated based on three biological and two technical replicates
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cytoskeletal dynamics was found to be differentially reg-
ulated according to different isoforms [21]. There are seven
mammalian 14-3-3 family members (b, c, e, r, n, s, g) that
are reported to be differently expressed between cell types
and a variety of tissues [22]. During this study we have
found two 14-3-3 isoforms: sigma (r) and eta (g) among
proteins characteristic for androgen-responding prostate
cancer cells in VVL-enriched fractions as a result of
interactions with series of glycoproteins, simultaneously
absent in androgen-independent cells. These isoforms may
have an impact on the loss of androgen dependency in
prostate cancer cells, and may serve as an indicator of cell
status. Possible mechanism might involve the recently
described interactions with exonuclease 1 (Q9UQ84),
where they function as apoptosis inducers, following DNA
damage [23]. Epsilon isoform was identified in both cell
types, and isolated by both VVL and PHA-Lectins. Finally,
b, c, n, and s isoforms were found in VVL-precipitated
fractions from DU145 cell homogenate. The principal
regulatory mechanisms responsible for controlling the
cellular levels of different 14-3-3 isoforms are still poorly
understood. However, the sigma and eta isoforms are often
described as tumor suppressors and their expression is up-
regulated in cancer recurrent, while the remaining isoforms
can work as potential oncogenes [24]. The main efforts on
14-3-3 biology in humans have been focused on their
possible interactions and modifications of the enzymes
functions that are of crucial importance in metabolic reg-
ulation [25, 26]. Presently, only a small fraction of 14-3-3
family have been thoroughly analyzed, despite the fact that
there is a growing evidence for several hundred various
binding partners [27]. In cancer progression, a key property
of metastatic cells is the ability to migrate, and the first step
in cell migration is modification of actin cytoskeleton.
There are a number of proteins involved in actin remod-
eling that have been identified as 14-3-3 binding partners
[28]. There is also an increasing evidence on the role of
14-3-3 as a transporter of binding partners to the cell
membrane; however, further investigations are required to
exploit the potential of the 14-3-3 proteins as drug targets.
Protein function is not only determined by the amino
acid sequence, but also by various posttranslational modi-
fications (PTM’s) that alter its biological role and affect
formation of complexes with other molecules. Pathological
changes influence the synthesis and metabolism of proteins
and also modify interactions between them. This is par-
ticularly important in tumor growth and proliferation where
the cells escape many control mechanisms. Serum derived
from cancer patients typically contains complex protein
patterns, often indirectly related to cancer disease. We
believe that identification of the reliable cancer biomarkers
in such complex mixture is a difficult task due to many
ambiguities associated with detailed and reproducible
analysis of serum proteins [29]. For instance, based on the
Fig. 4 Interaction network of identified proteins visualized by Osprey Platform (BioGRID Database version 3.2.96)
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gene expression studies on glycotransferases, only 1 % of
the glycoprotein population is altered [2]. Therefore, we
designed our experiments with culture cells, where glyco-
proteins are at much more abundant level, biological
material is more homogenous and reproducible. In the view
of the fact, that it is very challenging to generate a specific
antibody against particular glycan structure, we employed
lectins and their binding affinities toward sugar moieties
for enrichment of samples. Lectins and carbohydrates are
linked by a number of weak, non-covalent interactions.
Their binding sites tend to be of a relatively low affinity,
although they can exhibit high specificity. In addition, the
lectin-binding specificity is determined by the amino acid
residues that bind the glycan. Protein–protein interactions
are considered to be much stronger than the binding of
lectins to glycans; therefore the presence of non-glycosyl-
ated proteins in LAC-enriched fractions is well explicable.
Process of hormone sensitivity deprivation in prostate
tumors leads to a multi-step cascade of cellular events, by
which cancer cells escape control mechanisms and leave
the original tumor mass to establish new colonies at distant
sites in the body. To understand this mechanism, changes
in glycoprotein-enriched profiles present as a result of
androgen dependency loss were studied among proteins
characteristic for the DU145 and LNCaP cells. The
obtained results suggest that cell surface nucleolin, which
is implicated in cell proliferation, tumor cell growth and
angiogenesis, is relocated within the cell to the membrane,
in addition to Tn antigen attachment [14]. Moreover, 14-3-
3 protein isoforms r and g seem to control key activities
that may result in metabolic alteration and, as a conse-
quence, may lead to cancer development [24, 25]. Both
14-3-3 isoforms g and r significantly stimulate human
exonuclease 1 activity, indicating that these regulatory
proteins exert a common regulatory impact on hEXO1
[21]. Co-transfection of 14-3-3 leads to the enhanced
tumorigenesis. Altogether these and our data anticipate that
the cell tends to minimize proliferation of tumor-related
pathways by lowering the level of 14-3-3 g and r.
Described proteins may affect androgen administration,
and might be involved in the development and progression
of tumor, but also may lead to the failure of hormone
ablation therapy.
The results of this study revealed that glycoprotein-
enriched profile changes might serve as the putative
prognostic marker that allows for differentiation between
patients with PCa in the group responding to hormonal
therapy and those who do not exert any positive effects.
Therefore, our findings may have substantial impact,
helping to target those individuals who urgently need
radical intervention, while avoiding pharmacological
overtreatment or incorrect diagnosis. The discovery of
changes in proteome for tumor staging and monitoring PCa
would greatly facilitate our understanding of the mecha-
nism of androgen dependency loss.
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